减少慢性阿片类药物使用:乳房切除术后加速康复方案(ERAS)的长期影响
该单中心回顾性研究纳入2013年1月至2019年12月行乳房切除术(伴或不伴植入物乳房重建)的756例患者,比较2017年2月实施ERAS方案前后的慢性阿片类和镇静药物使用情况。ERAS组慢性阿片类使用几率降低(OR=0.57,95%CI:0.42-0.76),慢性镇静药物使用无增加。
要点
- ERAS方案实施后,初治(opioid-naive)患者慢性阿片类使用从40%降至30%(P=0.024),阿片耐受(opioid-tolerant)患者从58%降至37%(P=0.002)。
- 全部ERAS患者慢性阿片类使用几率降低(OR=0.57,95%CI:0.42-0.76)。
- 双侧手术(OR=1.54)、两阶段重建(OR=9.78)、较高PACU疼痛评分(OR=1.09)及出院OME>150(OR=2.63)与慢性阿片类使用几率增加相关。
核心结论
- ERAS方案与乳房切除术(伴或不伴植入物乳房重建)患者慢性阿片类使用减少相关,且未伴随慢性镇静药物使用的增加。
研究设计与样本
- 单中心回顾性研究,纳入2013年1月至2019年12月行乳房切除术伴或不伴植入物乳房重建的全部患者;ERAS方案于2017年2月实施,分为ERAS前组(405例)和ERAS组(351例),共756例。
主要发现
- ERAS实施后,初治患者慢性阿片类使用从40%降至30%(P=0.024),阿片耐受患者从58%降至37%(P=0.002),慢性镇静药物使用无增加。
- 全部ERAS患者慢性阿片类使用几率降低(OR=0.57,95%CI:0.42-0.76)。
- 在植入物乳房重建患者中,接受皮下植入物的患者慢性阿片类使用几率降低(OR=0.31,95%CI:0.20-0.48)。
- 双侧手术(OR=1.54,95%CI:1.14-2.08)、两阶段重建(OR=9.78,95%CI:5.94-16.09)、较高PACU疼痛评分(OR=1.09,95%CI:1.03-1.14)及出院OME>150(OR=2.63,95%CI:1.48-4.68)与慢性阿片类使用几率增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigates Enhanced Recovery After Surgery (ERAS) protocols' impact on long-term opioid and sedative use following mastectomy with or without implant-based breast reconstruction (IBBR). BACKGROUND: ERAS protocols for patients undergoing mastectomy with or without IBBR are associated with decreased length of stay, increased rate of same-day discharge, decreased postoperative pain, and decreased postoperative opioid requirements. However, less is known about their effect on opioid and sedative use beyond 90 days after surgery. METHODS: A retrospective review of all patients undergoing mastectomy with or without IBBR at a single institution between January 2013 and December 2019. Mastectomy ERAS protocols were implemented in February 2017, creating 2 groups: pre-ERAS and ERAS. Baseline characteristics and prevalence of chronic opioid and sedative use were compared. Univariable and multivariable logistic regression predicted factors associated with increased odds of chronic opioid and sedative use. RESULTS: A total of 756 patients were evaluated: 405 pre-ERAS and 351 ERAS. Post-ERAS, chronic opioid use decreased in opioid-naive (40% vs 30%, P =0.024) and opioid-tolerant patients (58% vs 37%, P =0.002), with no increase in chronic sedative use. There were decreased odds of chronic opioid use for all ERAS patients (OR=0.57, 95% CI: 0.42-0.76), and of IBBR patients, those receiving subcutaneous implants (OR=0.31, 95% CI: 0.20-0.48). There was increased chronic opioid-use odds if undergoing bilateral surgery (OR=1.54, 95% CI: 1.14-2.08), 2-stage reconstruction (OR=9.78, 95% CI: 5.94-16.09), and for patients with higher PACU pain scores (OR=1.09, 95% CI: 1.03-1.14) or >150 discharge OMEs (OR=2.63, 95% CI: 1.48-4.68). CONCLUSION: ERAS protocols for mastectomy patients with or without IBR are associated with decreases in chronic opioid use, without concomitant increases in chronic sedative use.
引用
- Jogerst K, Gupta N, Kosiorek HE, et al. Reducing Chronic Opioid Use: Long-term Impacts of Enhanced Recovery After Mastectomy Protocols. Ann Surg. 2024. PMID: 38757265. doi:10.1097/SLA.0000000000006344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。